Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medication Adherence | 33 | 2025 | 398 | 9.960 |
Why?
|
| Medicare Part C | 12 | 2025 | 38 | 5.720 |
Why?
|
| Motivational Interviewing | 7 | 2023 | 47 | 4.740 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2025 | 734 | 4.370 |
Why?
|
| Hypertension | 13 | 2025 | 1330 | 3.820 |
Why?
|
| Hyperlipidemias | 5 | 2022 | 178 | 3.290 |
Why?
|
| Atrial Fibrillation | 6 | 2025 | 660 | 2.760 |
Why?
|
| Diabetes Mellitus | 10 | 2025 | 874 | 2.720 |
Why?
|
| Smoking Cessation | 7 | 2016 | 198 | 2.680 |
Why?
|
| Antihypertensive Agents | 6 | 2025 | 414 | 2.620 |
Why?
|
| Anticoagulants | 5 | 2025 | 593 | 2.480 |
Why?
|
| Smoking | 8 | 2016 | 1051 | 1.840 |
Why?
|
| Angiotensin Receptor Antagonists | 7 | 2025 | 128 | 1.840 |
Why?
|
| United States | 40 | 2025 | 10916 | 1.750 |
Why?
|
| Aged | 46 | 2025 | 19871 | 1.750 |
Why?
|
| Hypoglycemic Agents | 4 | 2025 | 444 | 1.720 |
Why?
|
| Retrospective Studies | 47 | 2025 | 16353 | 1.590 |
Why?
|
| Medicare | 14 | 2024 | 428 | 1.580 |
Why?
|
| Medicare Part D | 2 | 2021 | 17 | 1.400 |
Why?
|
| Cardiovascular Diseases | 7 | 2025 | 1970 | 1.260 |
Why?
|
| Pharmaceutical Services | 3 | 2021 | 35 | 1.220 |
Why?
|
| Administration, Oral | 7 | 2025 | 684 | 1.130 |
Why?
|
| Stroke | 3 | 2025 | 989 | 1.100 |
Why?
|
| Rivaroxaban | 2 | 2024 | 55 | 1.100 |
Why?
|
| Factor Xa Inhibitors | 2 | 2024 | 64 | 1.080 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 6598 | 1.060 |
Why?
|
| Pyridones | 2 | 2024 | 119 | 1.060 |
Why?
|
| Markov Chains | 2 | 2024 | 83 | 1.060 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 112 | 1.040 |
Why?
|
| Multiple Myeloma | 2 | 2025 | 161 | 1.030 |
Why?
|
| Breast Neoplasms | 11 | 2025 | 2513 | 1.010 |
Why?
|
| Varenicline | 2 | 2016 | 14 | 1.010 |
Why?
|
| Antipsychotic Agents | 6 | 2024 | 371 | 1.010 |
Why?
|
| Bupropion | 2 | 2016 | 28 | 1.000 |
Why?
|
| Humans | 82 | 2025 | 125195 | 0.970 |
Why?
|
| Pyrazoles | 2 | 2024 | 305 | 0.940 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2023 | 225 | 0.930 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 510 | 0.910 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 1271 | 0.900 |
Why?
|
| Female | 58 | 2025 | 66807 | 0.890 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 94 | 0.890 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2021 | 15 | 0.890 |
Why?
|
| Drug Therapy, Combination | 6 | 2025 | 1172 | 0.890 |
Why?
|
| Hemorrhage | 2 | 2025 | 470 | 0.880 |
Why?
|
| Obesity | 6 | 2023 | 2248 | 0.840 |
Why?
|
| Male | 48 | 2025 | 61526 | 0.840 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2019 | 731 | 0.830 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2025 | 1140 | 0.820 |
Why?
|
| Middle Aged | 30 | 2025 | 26928 | 0.770 |
Why?
|
| Warfarin | 2 | 2022 | 119 | 0.760 |
Why?
|
| Texas | 14 | 2024 | 3588 | 0.760 |
Why?
|
| Students | 3 | 2013 | 249 | 0.760 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1251 | 0.750 |
Why?
|
| Logistic Models | 11 | 2021 | 1810 | 0.730 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 723 | 0.700 |
Why?
|
| Students, Pharmacy | 2 | 2019 | 64 | 0.660 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2024 | 100 | 0.650 |
Why?
|
| Weight Gain | 3 | 2024 | 400 | 0.640 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 76 | 0.640 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 126 | 0.640 |
Why?
|
| Benchmarking | 1 | 2020 | 137 | 0.630 |
Why?
|
| Cancer Survivors | 2 | 2018 | 211 | 0.600 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 104 | 0.600 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 219 | 0.590 |
Why?
|
| Buprenorphine | 3 | 2025 | 95 | 0.570 |
Why?
|
| Hospitalization | 3 | 2020 | 1783 | 0.560 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 302 | 0.550 |
Why?
|
| Health Care Costs | 1 | 2020 | 372 | 0.550 |
Why?
|
| Adult | 30 | 2025 | 29628 | 0.540 |
Why?
|
| Cross-Sectional Studies | 15 | 2025 | 3425 | 0.530 |
Why?
|
| Patient Readmission | 1 | 2020 | 385 | 0.520 |
Why?
|
| Drug Combinations | 4 | 2020 | 267 | 0.510 |
Why?
|
| Arabs | 1 | 2015 | 29 | 0.500 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 82 | 0.500 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 34 | 0.500 |
Why?
|
| Opioid-Related Disorders | 3 | 2025 | 260 | 0.490 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 45 | 0.490 |
Why?
|
| Tobacco Products | 1 | 2015 | 61 | 0.480 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 90 | 0.480 |
Why?
|
| Universities | 3 | 2013 | 125 | 0.480 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 130 | 0.470 |
Why?
|
| Primary Health Care | 1 | 2021 | 771 | 0.460 |
Why?
|
| Young Adult | 13 | 2025 | 9052 | 0.440 |
Why?
|
| Schizophrenia | 1 | 2016 | 311 | 0.420 |
Why?
|
| Telephone | 3 | 2019 | 110 | 0.410 |
Why?
|
| Health Behavior | 1 | 2015 | 385 | 0.400 |
Why?
|
| Pharmacists | 3 | 2020 | 84 | 0.400 |
Why?
|
| Medicaid | 3 | 2024 | 243 | 0.400 |
Why?
|
| Social Perception | 1 | 2013 | 56 | 0.390 |
Why?
|
| Risk-Taking | 2 | 2012 | 96 | 0.390 |
Why?
|
| Nicotine | 1 | 2013 | 142 | 0.370 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2025 | 541 | 0.370 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2016 | 10 | 0.360 |
Why?
|
| Cyclin-Dependent Kinase 4 | 3 | 2025 | 59 | 0.340 |
Why?
|
| Opiate Substitution Treatment | 3 | 2025 | 25 | 0.330 |
Why?
|
| Social Class | 2 | 2024 | 190 | 0.320 |
Why?
|
| Physicians | 4 | 2019 | 587 | 0.310 |
Why?
|
| Disease Management | 1 | 2012 | 528 | 0.300 |
Why?
|
| Patient Compliance | 2 | 2015 | 473 | 0.290 |
Why?
|
| Hydrocodone | 2 | 2019 | 32 | 0.290 |
Why?
|
| Blood Glucose | 4 | 2024 | 1131 | 0.290 |
Why?
|
| Adolescent | 15 | 2024 | 19362 | 0.290 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2025 | 41 | 0.290 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2024 | 24 | 0.280 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 257 | 0.280 |
Why?
|
| Body Mass Index | 6 | 2024 | 1565 | 0.270 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 798 | 0.270 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 1360 | 0.260 |
Why?
|
| Analgesics, Opioid | 3 | 2024 | 404 | 0.260 |
Why?
|
| Polypharmacy | 1 | 2005 | 40 | 0.250 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 606 | 0.240 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5176 | 0.240 |
Why?
|
| Proteasome Inhibitors | 1 | 2025 | 60 | 0.240 |
Why?
|
| Risk Factors | 8 | 2024 | 10315 | 0.240 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 22 | 0.230 |
Why?
|
| Aromatase Inhibitors | 3 | 2020 | 76 | 0.230 |
Why?
|
| Dabigatran | 1 | 2024 | 27 | 0.220 |
Why?
|
| Narcotic Antagonists | 1 | 2025 | 109 | 0.220 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1324 | 0.220 |
Why?
|
| Thalidomide | 1 | 2024 | 36 | 0.220 |
Why?
|
| Delirium | 1 | 2024 | 55 | 0.220 |
Why?
|
| Ambulatory Care | 2 | 2020 | 390 | 0.210 |
Why?
|
| Confidence Intervals | 3 | 2013 | 286 | 0.210 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 133 | 0.210 |
Why?
|
| Hypolipidemic Agents | 1 | 2004 | 182 | 0.200 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2022 | 11 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2024 | 1179 | 0.200 |
Why?
|
| Antidepressive Agents | 1 | 2025 | 293 | 0.200 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2022 | 59 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2024 | 228 | 0.190 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 434 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2023 | 1056 | 0.180 |
Why?
|
| Cognition Disorders | 1 | 2005 | 550 | 0.180 |
Why?
|
| Pharmacies | 1 | 2021 | 13 | 0.180 |
Why?
|
| Qualitative Research | 1 | 2024 | 539 | 0.180 |
Why?
|
| Pharmacy | 1 | 2021 | 13 | 0.180 |
Why?
|
| Surveys and Questionnaires | 6 | 2023 | 3730 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2022 | 104 | 0.180 |
Why?
|
| Health Surveys | 2 | 2012 | 244 | 0.180 |
Why?
|
| HIV Infections | 3 | 2023 | 1899 | 0.180 |
Why?
|
| Comorbidity | 2 | 2016 | 1534 | 0.170 |
Why?
|
| Tamoxifen | 2 | 2020 | 363 | 0.170 |
Why?
|
| Odds Ratio | 3 | 2013 | 1259 | 0.170 |
Why?
|
| Diabetes Complications | 1 | 2022 | 203 | 0.170 |
Why?
|
| Metformin | 1 | 2022 | 151 | 0.170 |
Why?
|
| Controlled Substances | 2 | 2019 | 11 | 0.170 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 15 | 0.170 |
Why?
|
| Neomycin | 1 | 2020 | 37 | 0.170 |
Why?
|
| Lactulose | 1 | 2020 | 39 | 0.170 |
Why?
|
| Sex Factors | 2 | 2019 | 1289 | 0.170 |
Why?
|
| Sexual Behavior | 2 | 2013 | 247 | 0.160 |
Why?
|
| Receptor, ErbB-2 | 4 | 2025 | 515 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2022 | 854 | 0.160 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 62 | 0.160 |
Why?
|
| Acute Pain | 1 | 2019 | 17 | 0.160 |
Why?
|
| Military Personnel | 2 | 2013 | 210 | 0.160 |
Why?
|
| Forecasting | 1 | 2021 | 351 | 0.160 |
Why?
|
| Psychological Theory | 2 | 2016 | 35 | 0.160 |
Why?
|
| Treatment Outcome | 3 | 2025 | 12392 | 0.160 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 460 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 173 | 0.150 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 343 | 0.150 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 571 | 0.150 |
Why?
|
| Intention | 2 | 2016 | 93 | 0.150 |
Why?
|
| Quinolines | 1 | 2019 | 98 | 0.150 |
Why?
|
| Health Services | 1 | 2018 | 71 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2022 | 425 | 0.150 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2021 | 224 | 0.150 |
Why?
|
| Standard of Care | 1 | 2018 | 130 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 1438 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2019 | 6153 | 0.140 |
Why?
|
| Health Care Surveys | 2 | 2019 | 285 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2019 | 443 | 0.140 |
Why?
|
| Chronic Pain | 1 | 2019 | 126 | 0.140 |
Why?
|
| Age Factors | 2 | 2019 | 2823 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 290 | 0.140 |
Why?
|
| Insulin Resistance | 1 | 2022 | 641 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2021 | 1197 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 183 | 0.140 |
Why?
|
| Perception | 2 | 2022 | 220 | 0.130 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 178 | 0.130 |
Why?
|
| Middle East | 2 | 2016 | 34 | 0.130 |
Why?
|
| Depression | 1 | 2025 | 1237 | 0.130 |
Why?
|
| Smoking Prevention | 1 | 2016 | 37 | 0.130 |
Why?
|
| Recurrence | 1 | 2020 | 1420 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2023 | 828 | 0.130 |
Why?
|
| Health Planning Guidelines | 1 | 2016 | 32 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 25 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2020 | 1396 | 0.120 |
Why?
|
| Self-Injurious Behavior | 1 | 2016 | 63 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 683 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 429 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2018 | 4817 | 0.120 |
Why?
|
| Cholinergic Antagonists | 2 | 2024 | 51 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 756 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2019 | 1375 | 0.110 |
Why?
|
| Propylene Glycol | 1 | 2013 | 9 | 0.100 |
Why?
|
| Child | 8 | 2024 | 24422 | 0.100 |
Why?
|
| Social Values | 1 | 2013 | 47 | 0.100 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2013 | 57 | 0.100 |
Why?
|
| Pakistan | 1 | 2012 | 81 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2013 | 91 | 0.100 |
Why?
|
| Jordan | 1 | 2012 | 8 | 0.100 |
Why?
|
| India | 1 | 2012 | 211 | 0.100 |
Why?
|
| Focus Groups | 1 | 2013 | 198 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 362 | 0.090 |
Why?
|
| Sunlight | 1 | 2011 | 24 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 604 | 0.090 |
Why?
|
| Overweight | 1 | 2014 | 364 | 0.090 |
Why?
|
| Data Collection | 1 | 2013 | 381 | 0.090 |
Why?
|
| Health Personnel | 1 | 2016 | 507 | 0.090 |
Why?
|
| Self Report | 1 | 2014 | 517 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 121 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 73 | 0.090 |
Why?
|
| Cholesterol | 2 | 2023 | 541 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 161 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 267 | 0.080 |
Why?
|
| Receptors, Estrogen | 2 | 2025 | 794 | 0.080 |
Why?
|
| Receptors, Progesterone | 2 | 2025 | 877 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2431 | 0.070 |
Why?
|
| Drug and Narcotic Control | 2 | 2019 | 17 | 0.070 |
Why?
|
| Incidence | 1 | 2015 | 3147 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 363 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2025 | 872 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3300 | 0.060 |
Why?
|
| New England | 1 | 2004 | 12 | 0.060 |
Why?
|
| Purines | 1 | 2025 | 116 | 0.060 |
Why?
|
| Aminopyridines | 1 | 2025 | 55 | 0.060 |
Why?
|
| Child Psychiatry | 1 | 2024 | 16 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2005 | 161 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2025 | 134 | 0.060 |
Why?
|
| Aripiprazole | 1 | 2024 | 20 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 729 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2005 | 781 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2004 | 78 | 0.050 |
Why?
|
| Pyridines | 1 | 2025 | 231 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2023 | 66 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2005 | 278 | 0.050 |
Why?
|
| Piperazines | 1 | 2025 | 241 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2024 | 170 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 371 | 0.050 |
Why?
|
| Mortality | 1 | 2004 | 238 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2024 | 174 | 0.050 |
Why?
|
| Health Status | 1 | 2024 | 377 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2022 | 61 | 0.050 |
Why?
|
| Obesity, Abdominal | 1 | 2022 | 38 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 100 | 0.050 |
Why?
|
| Nigeria | 2 | 2013 | 79 | 0.050 |
Why?
|
| Mexico | 1 | 2022 | 182 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 126 | 0.050 |
Why?
|
| Sexual Partners | 2 | 2013 | 87 | 0.050 |
Why?
|
| Neoplasms | 1 | 2016 | 2790 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 249 | 0.050 |
Why?
|
| Research | 1 | 2023 | 262 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2022 | 103 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2004 | 678 | 0.040 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 667 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 64 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 149 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 523 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 213 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 728 | 0.040 |
Why?
|
| Analgesics | 1 | 2019 | 127 | 0.040 |
Why?
|
| Survival Rate | 1 | 2023 | 2062 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 761 | 0.030 |
Why?
|
| United States Government Agencies | 1 | 2016 | 5 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1275 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1107 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 138 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2016 | 48 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2015 | 128 | 0.030 |
Why?
|
| Mammography | 1 | 2015 | 114 | 0.030 |
Why?
|
| SEER Program | 1 | 2015 | 202 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2013 | 38 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 249 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 722 | 0.030 |
Why?
|
| Methotrexate | 1 | 2015 | 334 | 0.030 |
Why?
|
| Communication | 1 | 2016 | 517 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 1435 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 96 | 0.020 |
Why?
|
| Condoms | 1 | 2010 | 49 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2010 | 199 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2024 | 14027 | 0.020 |
Why?
|
| Prevalence | 1 | 2011 | 2458 | 0.010 |
Why?
|
| Heart Failure | 1 | 2016 | 2298 | 0.010 |
Why?
|